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Abstract
 
Five CD1 molecules are expressed in humans and it is unclear whether they have specialized or
redundant functions. We found that sulfatide is a promiscuous CD1-binding ligand and have
isolated T cell clones that are specific for sulfatide and restricted by distinct CD1 molecules.
These clones have been used to compare the capacity of different CD1 to present the same gly-
colipid, to induce effector functions, and to form persistent immunogenic complexes. CD1a,
CD1b, and CD1c molecules similarly load sulfatide on the cell surface without processing, and
prime Th1 and Th2 responses. Stimulation by sulfatide-loaded CD1a persists much longer than
that by CD1b and CD1c in living cells. Use of recombinant soluble CD1a confirmed the pro-
longed capacity to stimulate T cells. Moreover, other glycosphingolipids bind to all CD1,
which suggests the presence of additional promiscuous ligands. Thus, group I CD1 molecules
present an overlapping set of self-glycolipids, even though they are quite divergent from an
evolutionary point of view.
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Introduction
 
T cells recognize foreign proteins as small peptides pre-
sented by MHC antigen-presenting molecules. In addition,
some T cells recognize exogenous glycolipids associated
with MHC-like CD1 molecules (1–3). Human APC may
express five types of CD1 molecules that are grouped into
two families. Group I includes CD1a, CD1b, CD1c, and
CD1e, whereas group II is represented only by CD1d.
CD1 molecules are predicted to share similar structures. All
of them bind and present glycolipids to specific T cells.
In some aspects, the immunogenicity of glycolipids par-
allels that of proteins. Like exogenous proteins, certain gly-
colipids require internalization into APC to form com-
plexes with CD1 molecules (4). Instead, other glycolipids
associate with CD1 molecules on the cell surface (5–7),
thus resembling small peptides that bind to MHC mole-
cules without being internalized. Like proteins, glycolipids
may also be subject to processing to give rise to immuno-
genic complexes with CD1 molecules. One example of a
synthetic glycolipid containing a disaccharide that becomes
stimulatory after endosomal processing has recently been
described (8). However, this is not a general rule because
glycolipids that bear large carbohydrates bind to CD1 and
efficiently stimulate T cells without any processing (6).
Therefore, the presence of large carbohydrates is compati-
ble with CD1 binding and TCR interaction.
The formation of stable complexes between the antigen
and the presenting molecule is an important shared prop-
erty of MHC and CD1 systems. The capacity of MHC
molecules to anchor the peptidic antigen is dependent on
intimate interactions between pockets in the MHC struc-
ture and specific amino acids in the bound peptide. Similar
direct interactions also occur between CD1 molecules and
glycolipids. Within the CD1 groove there are two large
hydrophobic pockets that anchor the lipid tails of glycolip-
ids (9, 10). Although the peptide structural requirements
for binding to MHC alleles have been thoroughly investi-
gated, the lipid structural requirements for CD1 binding
are only partially understood.
In contrast to MHC molecules, there is no evidence of
the existence of functionally relevant CD1 alleles. It is also
not known whether the five CD1 molecules represent a re-
dundant system for presentation of glycolipids to T cells, or
whether during evolution each CD1 isotype has acquired
individual properties of unique physiological relevance.
One important distinction between the different CD1
molecules is that they recycle and may load exogenous an-
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tigens in distinct intracellular compartments (7, 11, 12).
This feature might specialize each CD1 molecule in sur-
veillance of infectious agents confined within different cel-
lular organelles (7).
A second difference is the tissue distribution of CD1
molecules. CD1a, CD1b, and CD1c molecules are ex-
pressed on cortical thymocytes, on dendritic cells (DC)
 
*
 
 in
both lymphoid and nonlymphoid organs, and are inducible
by exposure to GM-CSF (13). However, CD1a is highly
expressed by Langerhans cells in the dermis and epidermis,
whereas CD1b is present in macrophages infiltrating
chronic inflammatory areas, such as atheromatous plaques
(14), nerve fibers in polyradiculoneuropathy (15), and de-
myelinating areas of brain in multiple sclerosis patients
(16). Instead, CD1c is expressed on a subpopulation of cir-
culating B cells, in the mantle zone of the spleen, and in
tonsillar B cells (17). It is unclear whether the unequal tis-
sue distribution reflects a nonredundant function of indi-
vidual CD1 molecules.
So far it has been difficult to evaluate the possible redun-
dancy in the CD1 system. One important issue is whether
CD1 molecules have developed the capacity to bind differ-
ent ligands, or whether they present the same glycolipids to
T cells. If they present overlapping sets of glycolipids, T
cells specific for the same antigen but restricted by different
CD1 may be recruited in vivo to different anatomical sites,
according to the distribution of CD1
 
 
 
 APC. This would
increase the number of T cells recognizing that same anti-
gen and have important implications for both antimicrobial
and autoimmune responses. A second important issue is
whether different CD1 molecules form complexes of
equivalent or differing immunogenic potential. Light on
this issue would clarify whether there is preferential stimu-
lation of T cells by the different CD1 molecules. Differences
in CD1 immunogenicity would have direct implications
for the development of new vaccines based on CD1-bind-
ing glycolipids.
This study has addressed these two issues by comparing
antigen presentation among CD1 molecules. The experi-
mental model selected was T cell recognition of sulfatide.
Sulfatide is made by a galactose sugar, modified by a sulfate
ester in position 3, and connected with a 
 
 
 
-glycosidic bond
to a ceramide. Ceramides are amides of acyl groups with
long chain dihydroxy or trihydroxy bases, the most com-
mon in animals being C18 sphingosine. The acyl group of
ceramides is generally a long chain saturated or monounsat-
urated fatty acid. Sulfatide is formed from a galactosylcer-
amide molecule by a sulfotransferase reaction. This enzyme
is very active during the myelinization process. Interest-
ingly, sulfatide is also found in tissues that are very active in
sodium transport (kidney, salt glands, and gills). Here we
show that sulfatide is a promiscuous ligand that binds group
I CD1 molecules and is presented by CD1a, CD1b, and
CD1c to specific T cells.
 
Materials and Methods
 
Glycolipid Antigens. 
 
The following purified glycolipids were
purchased from Fluka: sulfatide, galactosylceramide (GalCer),
glucosylceramide (GlcCer), and sphingomyelin. Sulfatide, GM1,
and lactosylceramide (LacCer) were purchased from Matreya.
Semisynthetic sulfatide containing stearic acid or 
 
14
 
C-stearic acid
as acyl moiety was purchased from Anawa. Purified ganglioside
GM4 was kindly provided by S. Sonnino (University of Milano,
Milano, Italy). All the glycolipids were 98–99% pure according to
TLC analysis.
 
Desulfation of Sulfatide. 
 
The sulfate group of sulfatide was hy-
drolyzed essentially as described previously (18). In brief, 1 mg
sulfatide was incubated in 1 ml of methanol with 50 mM of HCl
at room temperature. After 16 h, 3 ml of chloroform, 0.5 ml of
methanol, and 1.1 ml of 0.2% Na
 
2
 
CO
 
3
 
 were added. The lower
phase was washed with 2 ml of chloroform:methanol:0.1 M KCl
(3:48:47, vol/vol) and then with 2 ml of chloroform:methanol:
H
 
2
 
O (3:48:47, vol/vol). Efficiency of sulfatide desulfation was
tested by TLC on Silica gel high performance thin layer chroma-
tography plates (Merck) using chloroform:methanol:0.25% KCl
(50:40:10, vol/vol) as run-in solvent. Glycolipids were visualized
by orcinol staining.
 
T Cell Clones and APCs. 
 
Sulfatide-specific T cell lines and
clones were derived as described previously (19). DC were iso-
lated from peripheral blood mononuclear cells by culturing in the
presence of IL-4 and recombinant GM-CSF, as described previ-
ously (13). Each preparation of DC was tested for the expression
of CD1 molecules using mAbs specific for CD1a (OKT6, ATCC
CRL8019; American Type Culture Collection), CD1b (WM-
25; Immunokontakt), and CD1c (L161; Instrumentation Labora-
tory). CD1a-, CD1b-, CD1c-, CD1d-, or mock-transfected
C1R lymphoblastoma cells (provided by S. Porcelli, Albert Ein-
stein College of Medicine, New York, NY) were used as APC in
some experiments.
 
Antigen Presentation Assays. 
 
DC (5 
 
 
 
 10
 
4
 
/well) or CD1-
transfected C1R cells (5 
 
 
 
 10
 
4
 
/well) in RPMI-1640 medium
containing 10% FCS were preincubated for 2 h at 37
 
 
 
C with son-
icated antigen (0.01–20 
 
 
 
M) before the addition of T cells (6 
 
 
 
10
 
4
 
/well in triplicate). Supernatants were harvested after 36 h and
released cytokines were measured by ELISA. TNF-
 
 
 
 and IFN-
 
 
 
were detected using sandwich ELISA kits according to manufac-
turer’s instruction (Instrumentation Laboratory). IL-4 was de-
tected using anti–IL-4 mAbs (BD PharMingen). Data are ex-
pressed as mean pg/ml 
 
  
 
SD of triplicates. All experiments were
repeated at least two times.
For antibody blocking experiments, DC were preincubated
with 3 
 
 
 
M of sulfatide and then with OKT6, WM25, or L161
mAbs, or with Fab fragments of TR66 mAbs (anti-CD3
 
 
 
) for 20
min before the addition of T cells. Anti-TCRV
 
 
 
9 mAbs were
used as the isotype-matched control.
 
Fixation of DC. 
 
DC were washed and suspended in PBS
(2–3 
 
 
 
 10
 
6
 
/ml) containing 0.05% glutaraldehyde for 30 s at 37
 
 
 
C.
Additional fixation was blocked with 0.2 M of lysine. The efficiency
of fixation was controlled by the [
 
3
 
H]thymidine incorporation of
fixed cells and also by the stimulation of an MHC class II–restricted
purified protein derivative (PPD)-specific T cell clone. In some ex-
periments, APC were first fixed and then washed and pulsed with
10 
 
 
 
M of sulfatide for 1 h before the addition of T cells.
To investigate the requirements for antigen internalization,
DC (10
 
6
 
) were preincubated for 1 h at 4
 
 
 
C, or at 37
 
 
 
C, in the
presence or absence of 80 
 
 
 
M of chloroquine, or 20 
 
 
 
M of mo-
nensin, and then pulsed with 10 
 
 
 
M of sulfatide for an additional
1 h. After washing, DC were fixed and used to stimulate T cells.
 
*
 
Abbreviations used in this paper:
 
 
 
 
 
2m, 
 
 
 
2 microglobulin; DC, dendritic
cells; GalCer, galactosylceramide; GlcCer, glucosylceramide; LacCer, lac-
tosylceramide; PPD, purified protein derivative; sCD1a, soluble CD1a. 
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Intracellular Staining for IL-4 and IFN-
 
 
 
. 
 
T cell lines estab-
lished for 12 d were used in these assays. Although the number of
sulfatide-specific T cells was small, this time point was chosen to
reduce in vitro bias for cytokine production. Intracellular staining
was performed on T cells activated by CD1a-, CD1b-, CD1c-, or
mock-transfected C1R cells pulsed with 10 
 
 
 
M of sulfatide. After
3 h, Brefeldin A (5 
 
 
 
g/ml; Sigma-Aldrich) was added and incu-
bated for an additional 12 h. After washing, the cells were fixed
with 2% of paraformaldehyde and permeabilized with 0.1% of sa-
ponin. Four color immunofluorescence analysis was performed
using anti–CD3-ECD (Immunotech), anti–CD25-FITC, anti–
IL-4–PE, and anti–IFN-
 
 
 
–allophycocyanin mAbs (all from BD
PharMingen). Cells were analyzed on a FACSVantage
 
®
 
 SE (Bec-
ton Dickinson), gated according to forward scatter and side scat-
ter, and then on the CD3
 
 
 
CD25
 
 
 
 double-positive population.
 
Displacement of Bound Sulfatide. 
 
Displacement studies were
performed by using fixed DC pulsed with 60 
 
 
 
M of sulfatide for
1 h at 37
 
 
 
C, and then extensively washed and plated (3 
 
 
 
 10
 
4
 
/
well) with various doses of other glycolipids (6–60 
 
 
 
M) for 1 h
before the addition of T cells (5 
 
 
 
 10
 
4
 
/well). Isopentenyl-pyro-
phosphate–specific V
 
 
 
9V
 
 
 
2 T cell clone G2B9 was used as the
negative control.
 
Persistence of CD1–Sulfatide Complexes. 
 
6 
 
 
 
 10
 
6 
 
of DC were
pulsed with 60 
 
 
 
M of sulfatide at 37
 
 
 
C for 2 h, and then washed
three times and plated (4 
 
 
 
 10
 
5
 
 cells/well) in triplicates. At differ-
ent time points, DC were again washed twice before the addition
of T cells (5 
 
 
 
 10
 
5
 
 cells/well). At each time point in control
wells, 10 
 
 
 
M of sulfatide was added to assess the maximal presen-
tation capacity of DC. Results are expressed as a percentage of
control at each time point. As another control, CD1a, CD1b, and
CD1c expression was tested by immunofluorescence, and median
fluorescence values did not change during the culture periods.
 
Generation of Soluble CD1a (sCD1a). 
 
Recombinant sCD1a
and 
 
 
 
2 microglobulin (
 
 
 
2m) were obtained as previously de-
scribed for soluble CD1b (6). In vitro refolding of CD1a 
 
 
 
2m was
done by dilution at pH 7.2 in the presence of sulfatide. After con-
centration on Amicon 10K, the refolded sCD1a–sulfatide com-
plexes were purified from aggregated proteins on a HiLoad 16/60
Superdex 200 column (Amersham Pharmacia Biotech). The purity
of soluble protein was 
 
 
 
90% as assessed by Coomassie staining.
 
Ligand Binding to sCD1a and T Cell Stimulation Assay. 
 
To test
the stability of sCD1a–sulfatide complexes, refolded sCD1a was
loaded with 2 
 
 
 
M of [
 
14
 
C]sulfatide at room temperature for 2 h.
The excess [
 
14
 
C]sulfatide was removed by size-exclusion chro-
matography using Superdex 200 10/30 column (Amersham
Pharmacia Biotech), and purified sCD1a–sulfatide complexes
were incubated for 1, 4, and 7 d at 18
 
 
 
C. At each time point,
dissociated [
 
14
 
C]sulfatide was separated by size-exclusion chro-
matography, and radioactivity associated with sCD1a was mea-
sured by liquid scintillation. To assess proper refolding, sCD1a
was tested in a sandwich ELISA using anti-
 
 
 
2m and anti-CD1a
mAbs.
For activation assays, 30 
 
 
 
g/ml of sCD1a was preincubated
with 10 
 
 
 
M of sulfatide and immobilized on 96-well plates. After
washing away the excess protein and sulfatide, T cells were plated
(1 
 
 
 
 10
 
5
 
/well) with 1 ng/ml of PMA. Released cytokines were
measured after 24 h of incubation.
 
Results
 
CD1a, CD1b, and CD1c Molecules Present Sulfatide to Spe-
cific T Cells. 
 
A panel of CD1-restricted T cell lines spe-
cific for sulfatide was established from peripheral blood of
 
multiple sclerosis patients and normal donors. T cell clones
were obtained by limiting dilution and scored for antigen
specificity and CD1 restriction using CD1-transfected
APC. A total of 58 sulfatide-specific T cell clones were iso-
lated from two different lines. Reverse transcription-PCR
analysis of the TCR BV genes of 26 clones showed that 9
out of 16 CD1a-restricted clones and 8 out of 10 CD1b-
restricted clones present different rearrangements (unpub-
lished data). It is reasonable to conceive that 
 
 
 
50% of the
58 isolated clones are different cells. Most of the T cell
clones only reacted to sulfatide-pulsed APC, whereas one
CD1a-restricted clone was also weakly activated by DC in
the absence of exogenous sulfatide (unpublished data).
These latter findings could be attributed to pulsing with
sulfatide present in the serum or produced by the APC
themselves. Interestingly, only DC, and not B cells trans-
fected with the CD1a gene, activated this clone.
Experiments conducted with CD1 transfectants showed
that 19 clones were restricted by CD1a, 38 by CD1b, and 1
by CD1c. Fig. 1, A–C shows three examples of clones,
each restricted by an individual CD1 molecule. The re-
striction by different CD1 molecules was confirmed by in-
hibition with specific relevant anti-CD1 mAbs, whereas
control irrelevant mAbs had no effects (Fig. 1, D and F).
Inhibition was also observed with anti-CD3
 
 
 
 mAb Fab
fragments (Fig. 1, D and F), implying TCR-mediated acti-
vation. Most of the clones were CD4
 
 
 
, and only four were
CD8
 
 
 
. All clones were TCR 
 
  
 
 
 
 and did not express the
invariant V
 
 
 
24/V
 
 
 
11 TCR present on NK T cells (un-
published data).
 
Fine Antigen Specificity of Sulfatide-reactive T Cells. 
 
The
above results show that sulfatide is a promiscuous ligand
capable of forming immunogenic complexes with all
group I CD1 molecules. As the bulk cell lines were estab-
lished using a highly pure preparation of sulfatide from
bovine brain, it was important to confirm that the stimu-
latory ligand is indeed sulfatide and not minor contaminat-
ing products. The following experiments confirmed that
sulfatide is the active ligand. First, when sulfatide was de-
sulfated (Fig. 2 D) it was no longer active (Fig. 2, A–C),
thus confirming the importance of the sulfate group. Sec-
ond, the purity of sulfatide was confirmed to be 
 
 
 
98% by
gas chromatography-mass spectrometry and its structure
was validated by 
 
1
 
H-nuclear magnetic resonance (unpub-
lished data). Third, dose response studies showed that most
of the clones were reactive even to doses of 1–10 nM (Fig.
2 E), thus making it unlikely that minor contaminants are
the stimulatory ligands. The fine antigen specificity of T
cell clones was also tested using a panel of highly pure
glycolipids. Only four clones weakly cross reacted with
 
  
 
GalCer, which lacks the sulfate group present in sul-
fatide. None of the clones reacted to either GlcCer, Lac-
Cer, GM4 (Fig. 2 E), sphingomyelin, or GM1 ganglioside
(unpublished data), all of which share the ceramide tail
with sulfatide. These findings confirm the sulfatide speci-
ficity of the isolated clones and demonstrate that their rec-
ognition is highly sensitive to changes in the carbohydrate
moiety of sulfatide. 
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Group I CD1 Molecules Show Common Sulfatide Presenta-
tion Requirements. 
 
The generation of T cell clones re-
stricted by different CD1 molecules and with the same
antigen specificity offered for the first time the possibility
of comparing the antigen presentation requirements of
CD1a, CD1b, and CD1c. DC, which express all of the
CD1 molecules, were pulsed with sulfatide at 4
 
 
 
C or in
the presence of monensin (to inhibit CD1 recycling) or
chloroquine (to block endosomal acidification). These
treatments did not inhibit sulfatide presentation by CD1a,
CD1b, or CD1c isoforms (Fig. 3, A–C), whereas they
completely inhibited presentation to MHC class II–restricted
T cells (Fig. 3 D). When DC were first fixed and then
pulsed with sulfatide, the T cell clones were also efficiently
activated (Fig. 3, A–C). Thus, neither internalization of
sulfatide, the presence of acidified endosomes, nor CD1
recycling are necessary for the generation of immunogenic
complexes between sulfatide and each of the three group I
CD1 molecules.
 
CD1 Restriction Does Not Influence the T Cell Functional
Phenotype. 
 
Next, we investigated whether restriction by
different CD1 molecules may influence lymphokine re-
lease. Evaluation of IL-4 and TNF-
 
 
 
 release by each T cell
clone after stimulation with sulfatide-pulsed DC showed
no bias by CD1 restriction. Clones showed a Th1, Th2, or
Th0 phenotype (Fig. 4). To estimate the extent of in vitro–
induced functional maturation, intracellular staining was
performed on two freshly established sulfatide-specific bulk
lines. Each line was challenged with CD1a-, CD1b-,
CD1c-, or mock-transfected APC and then intracellular
cytokines were studied. Anti-CD25 and anti-CD3 mAbs
were used to gate activated T cells, and anti–IL-4 and anti–
IFN-
 
 
 
 mAbs to detect these two intracellular cytokines
(Table I). A very small number of T cells (1%) up-regulated
CD25 in the absence of sulfatide, whereas a larger fraction
(3.5–11%) became CD25
 
 
 
 after stimulation with sulfatide
(unpublished data). The number of T cells up-regulating
CD25 in the presence of sulfatide was similar for the three
groups of CD1 transfectants. The analysis of intracellular
cytokines showed that most of the cells produce IL-4 or
IFN-
 
 
 
. Interestingly, only a few cells produced both lym-
phokines after sulfatide recognition.
Figure 1. Presentation of sulfatide
by CD1a, CD1b, and CD1c anti-
gen-presenting molecules. (A–C)
CD1a-, CD1b-, CD1c-, CD1d-, or
mock-transfected C1R cells were
pulsed with 10  M of sulfatide and
used to stimulate the following T
cell clones: K34B9.1 (A and D,
CD1a restricted), DS1C9b (B and E,
CD1b restricted) and DS1B9c (C
and F, CD1c restricted). Stimulation
in the presence (solid bars) or the ab-
sence (open bars) of sulfatide is
shown. (D–F) Presentation of sul-
fatide by DC to the specific T cell
clones was blocked by anti-CD1a
( ), anti-CD1b ( ), anti-CD1c
( ), or anti-TCR Fab ( ) frag-
ments, but not by isotype-matched
control mAbs ( ).
Figure 2. Fine antigen specificity of sulfatide-specific T cell clones. (A–C)
Desulfation abolishes immunogenicity of sulfatide. DC were incubated
with 10  M of sulfatide, mock-treated sulfatide, desulfated sulfatide, or
GalCer before the addition of the T cell clones K34B9.1 (A, CD1a re-
stricted), DS1C9b (B, CD1b restricted), and DS1B9c (C, CD1c re-
stricted). (D) Thin layer chromatographic analysis of GalCer (lane 1), sul-
fatide (lane 2), and sulfatide after desulfation (lane 3). (E) Dose response of
a representative T cell clone (K34B9.1, CD1a restricted) stimulated with
DC pulsed with sulfatide, GalCer, GlcCer, LacCer, and ganglioside
GM4. Similar results were obtained with most of the clones and also with
IL-4 ELISA (unpublished data). The results are representative of three in-
dependent experiments. 
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In conclusion, these experiments show that response to
sulfatide can be either of a Th1 or Th2 type.
 
CD1–Sulfatide Complexes Are Displaced by Other Glyco-
lipids.  We have previously shown that self-glycosphin-
golipids bound to CD1b molecules are readily displaced by
ligands that have an appropriate CD1b binding structure
(6). Therefore, we asked whether sulfatide bound to each
of the three CD1 molecules is displaceable. Fixed DC first
pulsed with sulfatide and then incubated with increasing
amounts of GM1 showed a reduced stimulation of all
CD1-restricted T cells (Fig. 5, A–C). The same concentra-
tion of GM1 did not influence the response of control
TCR    T cells to their specific ligand (Fig. 5 D). Al-
though GM1 at high doses almost completely eliminated T
cell responsiveness, sphingomyelin was much less inhibi-
tory even at high doses exceeding the critical micelle con-
centration (Fig. 5, A–C). Therefore, not all ligands con-
taining a ceramide tail displace CD1-bound antigens.
CD1a–Sulfatide Complexes Persist Longer than CD1b or
CD1c Complexes.  It is not known whether CD1 mole-
cules differ in their capacity to form long-lived complexes
with glycolipids. To address this issue, DC were pulsed
with sulfatide, washed extensively, and then chased for dif-
ferent times before the addition of T cell clones restricted
by different CD1 molecules. As positive controls, DC
treated as described above were also incubated with fresh
sulfatide to restore maximal presentation capacity before
the addition of T cells. In these experiments a high dose of
sulfatide was used to avoid a possible influence due to dif-
ferent antigen sensitivity of individual T cell clones. Stimu-
lation by CD1b– and CD1c–sulfatide complexes decreased
to 50% within 24 h and remained at  30% of the control
levels after 72 h. Surprisingly, CD1a continued to present
sulfatide with  80% efficiency after a 72-h chase (Fig. 6
A). This was confirmed using two different CD1a-
restricted sulfatide-specific T cell clones. In some experi-
ments DC were also washed before the addition of T cells
to avoid a possible reuptake of free sulfatide, and again sim-
ilar results were obtained (unpublished data). Furthermore,
DC did not change surface expression of CD1 molecules
over 72 h (unpublished data), thus excluding CD1 down-
modulation as a limiting condition. These findings indicate
that CD1a–sulfatide complexes generated in living cells are
immunogenic longer than complexes formed with CD1b
and CD1c.
Recombinant sCD1a–Sulfatide Complexes Are Stable and
Immunogenic.  To study the stability of CD1a–sulfatide
complexes, recombinant sCD1a molecules were generated.
Radioactive sulfatide remained significantly associated with
Figure 3. CD1a, CD1b, and
CD1c molecules do not require in-
ternalization and endosomal acidifi-
cation for sulfatide presentation.
DC were pretreated under differ-
ent conditions (as described in Ma-
terials and Methods), and then
pulsed with sulfatide and fixed be-
fore the addition of the T cell
clones K34B9.1 (A, CD1a re-
stricted), DS1C9b (B, CD1b re-
stricted), and DS1B9c (C, CD1c
restricted). (D) The same treatments
completely abolished the response of the clone GP2.7, which is specific for PPD and HLA-DR restricted. Fix-Pulse stands for the fixation of APC be-
fore pulsing with the antigen. Results are representative of three independent experiments.
Figure 4. Functional phenotype of CD1-restricted and sulfatide-spe-
cific T cell clones. DC pulsed with 10  M of sulfatide were used to stim-
ulate (A) CD1a- ( ), (B) CD1b- ( ), or CD1c-restricted ( ) T cell
clones. After 36 h the released IL-4 and TNF-  were detected by ELISA.
Results from 58 clones are shown.
Table I. Cytokine Production of Freshly Established T Cell Lines
Line APC IL-4  IFN-   IL-4  and IFN-  
1 Mock 0.05 0.21 0.04
CD1a 2.98 2.56 0.14
CD1b 1.62 2.34 0.05
CD1c 1.23 4.12 0.12
2 Mock 0.04 0.13 0.20
CD1a 0.18 4.52 0.10
CD1b 1.53 7.56 0.12
CD1c 1.16 1.42 0.50
Number represent percentage of CD3  cells stained with cytokine-
specific mAbs. Values represent the difference between groups
stimulated in the presence or absence of sulfatide.1018 Promiscuous Binding of Sulfatide to CD1
sCD1a for 7 d (71% of control values at time 0), even
when the samples were maintained at room temperature,
which shows a very stable interaction (Fig. 6 B). In similar
experiments soluble recombinant mouse CD1d- –GalCer
complexes lost T cell stimulatory capacity after a 24-h
chase (20).
Next, we studied whether the T cell stimulatory capacity
of recombinant CD1a–sulfatide complexes might also per-
sist for a long period as observed with living cells. The
sCD1a molecules appeared properly refolded, as demon-
strated by sandwich ELISA (unpublished data), because
they stimulated CD1a-restricted sulfatide-specific T cells,
but not T cells specific for another antigen (Fig. 6 C).
When sulfatide-loaded sCD1a molecules were immobi-
lized to plastic and chased for different times, they contin-
ued to stimulate specific T cells with an efficiency of 60%
even after a 72-h chase (Fig. 6 D). These results confirm
the data obtained with living cells, and clearly show that
CD1a–sulfatide complexes are very stable and maintain T
cell stimulatory capacity for a long time.
Discussion
Our results demonstrate that sulfatide can bind to CD1a,
CD1b, and CD1c molecules, and stimulate specific T cells.
Sulfatide is thus a promiscuous ligand for group I CD1
molecules and, in this respect, resembles promiscuous pep-
tides that bind to several MHC molecules and activate T
cells in a specific manner (21–23). The availability of a pro-
miscuous CD1 ligand facilitated a series of comparative
studies that were previously not possible with other known
self- or bacterial glycolipids. This study has addressed three
issues relevant to the physiology of glycolipid recognition
by T cells.
The first issue concerns antigen presentation similarities
and differences among group I CD1 molecules. Our data
show that CD1a, CD1b, and CD1c have several common
properties. Sulfatide is efficiently presented by all of them
in the absence of endosomal acidification, internalization,
and intracellular and extracellular processing. It remains to
be determined whether CD1 molecules share antigen load-
ing and presentation requirements for glycolipids that have
lipid tails distinct from ceramide.
Furthermore, all CD1–sulfatide complexes are displaced
by other glycolipids, which suggests that the immunoge-
nicity of CD1–glycolipid complexes can be conditioned by
the presence of other CD1 ligands. The importance of this
feature, which represents an original and flexible regulation
of antigen presentation for group I CD1 molecules, has to
be confirmed in vivo.
Figure 5. Sulfatide previously bound to CD1 is displaced by other gly-
colipids. (A–C) Fixed DC pulsed with high doses of sulfatide (60  M)
and then incubated with various doses of GM1 ( ) or sphingomyelin ( )
were used to stimulate the T cell clones K34B9.1 (A, CD1a restricted),
DS1C9b (B, CD1b restricted), and DS1B9c (C, CD1c restricted). (D) To
demonstrate the lack of toxicity, control V 9V 2 T cells activated by iso-
pentenyl pyrophosphate were included. The data shown is representative
of three independent experiments.
Figure 6. Persistence and stability of CD1–sulfatide complexes. (A)
DC pulsed with 60  M of sulfatide were used to stimulate the CD1a-
restricted T cell clones K34B9.1 and DS1A16a (  and  , respectively),
the CD1b-restricted clone DS1C9b ( ), or the CD1c-restricted clone
DS1B9c ( ). Results are expressed as a percentage of controls (as de-
scribed in Materials and Methods). (B) Soluble CD1a–[14C]sulfatide com-
plexes were incubated for the indicated time at room temperature and the
remaining radioactivity associated with sCD1a was measured after size ex-
clusion chromatography (as described in Materials and Methods). (C) Sol-
uble CD1a preincubated with sulfatide was immobilized and used to
stimulate the CD1a-restricted sulfatide-specific T cell clone K34B9.1
(solid bars) or the MHC class II–restricted PPD-specific GP2.9 clone
(open bars). Immobilized BSA or sulfatide were used as negative controls.
(D) Immobilized sCD1a–sulfatide complexes were chased for the indi-
cated time and used to stimulate the CD1a-restricted T cell clone
K34B9.1 (as described in Materials and Methods).1019 Shamshiev et al.
Our results also demonstrate that CD1 molecules are
characterized by relevant differences that mainly concern
the persistence of stimulatory complexes. CD1a–sulfatide
complexes remain immunogenic at least 72 h after chase.
CD1b and CD1c, in contrast, have much shorter persis-
tence, similar to that of mouse CD1d- –GalCer complexes
(20). Differential persistence may have several explanations.
The first is provided by the high stability of the CD1a–sul-
fatide complexes, as revealed by experiments with recom-
binant CD1a molecules. CD1a and sulfatide remain associ-
ated in vitro over a period of 7 d and retain the capacity to
stimulate T cells with high efficiency after 3 d of chase,
even when immobilized. A second explanation is that the
CD1–sulfatide complexes may differ in their susceptibility
to displacement by other glycolipids. This seems unlikely,
because all CD1–sulfatide complexes are displaced by
GM1. However, even if testing a larger variety of glycolip-
ids, this possibility cannot be excluded. A third explanation,
albeit not investigated in this study, is that the different in-
tracellular recycling pathways of individual CD1 molecules
(7, 11, 12) affect the persistence of CD1–sulfatide com-
plexes. Recycling in compartments with different pH
might directly influence the stability of CD1 molecules and
the binding of glycolipids.
Whatever the mechanism, what is of physiological im-
portance is that all types of CD1–sulfatide complexes persist
long enough to recruit specific T cells in vivo, and all are
potentially immunogenic. If prolonged persistence of
CD1a complexes is also applicable to other glycolipids, an-
tigen presentation by CD1a might be perceived as being
more efficient than that by other CD1 molecules. This hy-
pothesis deserves careful investigation and should be chal-
lenged using microbial ligands to evaluate its possible thera-
peutic implications.
The second issue concerns the relationship between the
sulfatide structure and its promiscuous binding to CD1.
Our results extend the notion of structural requirements for
CD1 binding. Sulfatide is composed of a ceramide tail
linked through a  -1 glycosidic bond to galactose modified
by a sulfate group. This is a small structure compared with
that of other glycosphingolipids such as GM1, GD1a,
GT1b, and GQ1a gangliosides, which are made of complex
carbohydrates with five to eight monosaccharides and also
activate specific T cells (6). It is unlikely that the promiscu-
ous binding of sulfatide to CD1 is due to its small glyco-
sidic moiety, because GM1, which is composed of five sug-
ars, displaces sulfatide bound to CD1a, CD1b, and CD1c
(Fig. 5), is presented by CD1b to specific T cells (6), and
associates with mouse (20, 24) and human CD1d (unpub-
lished data). Because the lipid moiety is responsible for an-
choring glycolipids to CD1 (9, 10), promiscuous binding
can be attributed to the ceramide tail, common to both sul-
fatide and gangliosides. Thus, and in consideration of avail-
able data from the literature (24, 25), ceramide might be
considered a universal anchor for all CD1 molecules.
A point to emphasize is that different CD1 molecules
can present the same lipids, although from an evolutionary
point of view they are quite divergent. This is not what the
analysis of CD1 restriction of the mycobacterial dolichol
phosphate ligand has implied (26). In that case the ob-
served predominant CD1c restriction could have arisen
from important differences in immunogenicity rather than
in binding capacity to individual CD1 molecules. It is diffi-
cult to envisage whether there is a biased CD1 binding in
the case of other mycobacterial antigens, such as mycolic
acid (27), lipoarabinomannan (4), and glucose monomyco-
late (28), which are presented by CD1b. This is due to the
small number of T cell clones with these antigen specifici-
ties that have been isolated and described, so far. If the pre-
sentation of an overlapping set of ligands is the common
rule, a major rationale for maintaining different CD1 mol-
ecules would be the pattern of tissue expression or perhaps
the patrol of different endosomal compartments (11) (not
as relevant for sulfatide), rather than the ability to present
different lipids.
A third issue concerns the significance of CD1 presenta-
tion of self-glycolipids and the functional role of specific T
cells. Self-glycolipids might represent low avidity ligands
with the function of selecting the CD1-restricted repertoire
in the thymus. In the periphery of normal donors these
ligands might instead facilitate the persistence of naive
CD1-restricted T cells, as reported for self-peptides that al-
low the survival of naive MHC-restricted T cells (29–31).
Our experimental findings show that the function of
self-glycolipid–reactive T cells is not biased by the CD1 re-
striction and that both Th1 and Th2 cells are primed by all
group I CD1 molecules. Thus, T cells reactive with self-
glycosphingolipids may function either as proinflammatory
or helper cells. It is not clear whether these are related to
disease, homeostasis, or both. We have found an increased
frequency of self-glycolipid–reactive T cells in patients
with multiple sclerosis. However, the same type of antigen
specificities were also detected in normal donors (6, 19),
thus leaving open each possibility. Because these autoreac-
tive lymphocytes are not always associated with disease,
they might exert important regulatory functions whenever
alterations of glycolipid production or presentation occur.
This raises questions as to whether T cell tolerance to self-
glycolipids exists and how such tolerance is broken. Sul-
fatide is one of the most abundant glycolipids in brain tis-
sue, an important constituent of almost all membranes, and
found in the serum at concentrations of 0.5–2.0  M (32).
Anti-sulfatide antibodies are present in normal donors and
have been observed in patients with peripheral neuropa-
thies associated with IgM paraproteinaemia, or after HIV
infection (33–35). In all of these instances, mainly IgM
anti-sulfatide antibodies are found. In contrast, prediabetic
and newly diagnosed type 1 diabetic patients, and those
with dilatative cardiomyopathy and developing Chagas’
disease after Trypanosoma cruzi infection, have exceptionally
high amounts of IgG anti-sulfatide antibodies (36, 37). In
these patients, the priming and expansion of pathogenic
sulfatide-specific Th cells could explain the presence of IgG
autoantibodies. In the case of Chagas’ disease, the priming
of T cells could be provided by trypanosomal glycolipids,
known to structurally resemble sulfatide (38). Thus, mim-1020 Promiscuous Binding of Sulfatide to CD1
icry of microbial ligands with self-glycolipids might repre-
sent a potential mechanism to prime autoreactive T cells
and break self-tolerance to glycolipids.
In conclusion, like peptides, some glycolipids behave
like promiscuous ligands by binding to different antigen-
presenting molecules and stimulating specific T cells. It re-
mains to be investigated how general this phenomenon is.
Promiscuous CD1 presentation of sulfatide adheres to
common rules including the stable binding to group I CD1
molecules, and is regulated by displacement with other
ligands. However, the CD1 complexes do not always be-
have identically and differ in their in vivo persistence,
which may bias antigen sampling and presentation. These
findings provide a framework to further dissect the cellular
and structural requirements for the formation, stability, and
immunogenicity of CD1–glycolipid complexes.
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